Special Issue "Tyrosine Kinase Signaling Pathways in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (15 September 2018).
Interests: cell pathology; cancer progression; cancer metastasis; targeted therapy; tyrosine kinase inhibitors
Protein Tyrosine Kinases (PTKs) represent the most studied topic in therapeutic oncology with several thousand of new publications per year. The interest in PTKs is due to their central role in the growth of nearly every cancer type. The early finding of BCR-ABL as effective target in curing chronic myeloid leukemia has opened a new era of the clinic oncology with the promise of non-toxic, manageable and highly specific therapies.
In the last few decades, the use of small molecules and antibodies as PTK inhibitors has confirmed that PTKs are the main drivers of fundamental processes in cancer initiation and progression, including self-sustained proliferation, migration, invasion and angiogenesis. At the same time, PTK targeted therapies have frequently produced in clinic trials unmet expectation, suggesting a lack of knowledge about the molecular control of oncogenic activation of PTKs.
The nearly one hundred of the known PTKs form a highly interconnected cellular signaling circuits that regulate in a pleiotropic and redundant manner the normal cellular communication and maintenance of homeostasis. In addition, during oncogenic transformation and progression, PTKs contribute to the aberrant phenotype and genotype through various mechanisms including enhanced expression, mutation and autocrine stimulation. In this landscape, strategies to inhibit PTKs in cancer offer still several open questions: The definition of driver and passenger PTK signaling pathways; the grade of selectivity of the PTK inhibitor to be used; the blockade of alternative/resistance PTK signaling pathways; the identification of personalized “kinome” signatures.
In this Special Issue, authors discuss the update information about PTK signaling circuits and the aberrant mechanisms associated with their oncogenic switch. Development of drugs directed against new PTK targets is also being explored. The critical evaluation of the current knowledge about PTKs is fundamental for the refinement of the current clinical therapeutic protocols and the establishment of future precision medicine.
Dr. Adriano Angelucci
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.